Cell death and the mitochondria: therapeutic targeting of the BCL‐2 family‐driven pathway
- 28 March 2014
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (8) , 1973-1987
Abstract
The principal biological role of mitochondria is to supply energy to cells; although intriguingly, evolution has bestowed another essential function upon these cellular organelles: under physiological stress, mitochondria become the cornerstone of apoptotic cell death. Specifically, mitochondrial outer membrane permeabilization (MOMP) allows cell death factors such as cytochrome c to be released into the cytoplasm, thus inducing caspase activation and the eventual destruction of essential cellular components. Proteins of the B‐cell lymphoma 2 (BCL‐2) family control the tightly regulated pathway that causes MOMP. The equilibrium between pro‐survival and pro‐apoptotic members of the BCL‐2 family dictates the fate of cells, the homeostasis of organs and, by extension, the health of whole organisms. Dysregulation of this equilibrium is involved in a large number of diseases such as cancer, autoimmunity and neurodegenerative conditions. Modulating the activity of the BCL‐2 family of proteins with small molecules or peptides is an attractive but challenging therapeutic goal. This review highlights the latest developments in this field and provides evidence that this strategy is likely to have a positive effect on the treatment of still poorly addressed medical conditions.Linked Articles: This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8Keywords
Funding Information
- National Health and Medical Research Council (GNT1025138)
- National Health and Medical Research Council (GNT1023055)
- Australian Research Council (FT0992105)
This publication has 144 references indexed in Scilit:
- Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic PrimingMolecular Cell, 2013
- Enhancement of α-Helix Mimicry by an α/β-Peptide Foldamer via Incorporation of a Dense Ionic Side-Chain ArrayJournal of the American Chemical Society, 2012
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the MitochondriaMolecular Cell, 2011
- Structural Basis of Bcl‐xL Recognition by a BH3‐Mimetic α/β‐Peptide Generated by Sequence‐Based DesignChemBioChem, 2011
- Bcl-xL Retrotranslocates Bax from the Mitochondria into the CytosolCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAXMolecular Cell, 2010
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- The Hallmarks of CancerCell, 2000